Search results for Opicinumab
Opicinumab Biosimilar – Anti-LINGO1, LRRN6A, LERN1 mAb – Research Grade, ProteoGenix, PX-TA1389
Description of Opicinumab Biosimilar - Anti-LINGO1, LRRN6A, LERN1 mAb - Research Grade General information on Anti-LINGO1/LRRN6A/LERN1[Homo sapiens] (Opicinumab) Monoclonal Antibody Opcinumab is investigated for the treatment of Central Nervous System (CNS) Demyelinating Disease and Multiple Sclerosis.
Host
Reactivity
Applications
Conjugation
Opicinumab, Abbexa, abx831348
Opicinumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting LINGO1/LRRN6A/LERN1, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Opicinumab is under investigation in clinical trial NCT02641041 (Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants).
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Opicinumab Biosimilar - Research Grade, ichor.bio, ICH5738
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Research Grade Opicinumab (HV367016), abinScience, HV367016
Host
Human
Reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Conjugation
Please provide the required information below so that we can quickly source your products.